Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.
Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, Hennrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka K. · 2014
Read Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. by Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, Hennrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka K. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4113732.txt.
Introduction
Matthias Eder, Klaus Kopka, and colleagues reported preclinical and production details for a radioactive tracer that images prostate cancer. Their paper appeared in Pharmaceuticals in 2014. The tracer targets PSMA, a protein on prostate cancer cells, and had already shown promise in first human scans.
The molecule pairs a PSMA-blocking unit with a chelator, HBED-CC, that grips the radioactive gallium label. Swapping in a standard chelator had wrecked image quality, proving HBED-CC itself helps the tracer bind its target. The chelator also labels fast at room temperature and holds the metal stably. The paper explains these chemistry advantages and adds new preclinical data plus practical aspects of making the tracer as a radiopharmaceutical for clinics.
Catalog record
| CREATOR | Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, Hennrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka K. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer By Matthias Eder, Oliver Neels, Miriam Müller, Ulrike Bauder-Wüst, Yvonne Remde, Martin Schäfer, Ute Hennrich, Michael Eisenhut, Ali Afshar-Oromieh, Uwe Haberkorn, Klaus Kopka Published in: Pharmaceuticals DOI: 10.3390/ph7070779 ABSTRACT The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recently demonstrated its suitability in individual first-in-man studies. The radiometal chelator HBED-CC used in this molecule represents a rather rarely used acyclic complexing agent with chemical characteristics favourably influencing the biological functionality of the PSMA inhibitor. The simple replacement of HBED-CC by the prominent radiometal chelator DOTA was shown to dramatically reduce the in vivo imaging quality of the respective 68Ga-labelled PSMA-targeted tracer proving that HBED-CC contributes intrinsically to the PSMA binding of the Glu-urea-Lys(Ahx) pharmacophore. Owing to the obvious growing clinical impact, this work aims to reflect the properties of HBED-CC as acyclic radiometal chelator and presents novel preclinical data and relevant aspects of the radiopharmaceutical production process of [68Ga]Ga-PSMA-HBED-CC. 1. INTRODUCTION Early detection of metastases or recurrent prostate cancer (PC) lesions is of utmost clinical relevance in terms of clinical staging, prognosis and therapy management [1,2]. The high clinical impact of targeting the prostate-specific membrane antigen (PSMA) was recently demonstrated in a series of first-in-man examinations with either 68Ga- [3,4,5] or 123I-labelled [6] PSMA inhibitors. PSMA is a membrane-type zinc protease, also called glutamate carboxypeptidase II (GCPII), which is expressed by nearly all prostate cancers. Enhanced expression levels were found in poorly differentiated, metastatic and hormone-refractory carcinomas [7,8]. Since urea-based inhibitors of PSMA clear rapidly from the circulation and since only low levels of physiological PSMA expression were detected in a few organs like the brain, kidney, salivary gland and small intestine [7,9,10,11] PSMA represents an ideal biological target for high quality PET imaging of prostate cancer [12,13,14,15,16,17]. Initial clinical experiences with the 68Ga-labelled PET tracer Glu-NH-CO-NH-Lys-(Ahx)-[[68Ga]Ga(HBED-CC)] ([68Ga]Ga-PSMA-HBED-CC) suggest that this novel tracer detects PC relapses and metastases with higher contrast as compared to 18F-choline. In a retrospective study, the images of 37 patients who received both 18F-choline PET/CT and 68Ga-PSMA PET/CT were analyzed [3]. Especially at low PSA values, PET/CT images obtained with [68Ga]Ga-PSMA-HBED-CC showed more PC lesions as compared to 18F-choline. It was concluded that [68Ga]Ga-PSMA-HBED-CC represents an attractive new imaging agent for the detection of recurrent prostate cancer and metastatic spread. The chelator HBED-CC (N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid), represents a hitherto rarely used acyclic complexing agent especially allowing efficient radiolabelling with 68Ga even at ambient temperature [18,19]. By combining HBED-CC with the PSMA inhibitor Glu-urea-Lys, a favourable aromatic part is introduced into the radiotracer which was found to be a necessary requirement for a sustainable interaction with the PSMA receptor, putatively with the accessory hydrophobic pocket of the PSMA S1 binding site [15,20,21]. We have indeed shown in a preclinical study that the replacement of HBED-CC by DOTA (1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid) resulted in a molecule not able to image the tumour at all [20]. Moreover, besides these biological advantages, HBED-CC represents a highly effective chelator. Extraordinary high thermodynamic stability constants of >1039 were determined for the complexation of Ga with HBED [22]. As mentioned before the structure is acyclic and demands rather low energy for complex formation which allows fast labelling at ambient temperature [19,20]. Moreover, a high kinetic stability of the Ga-HBED-CC complex at physiological pH was reported [23] resulting in a stable complex in vivo [24] and in human serum for at least 72 h [25]. Thus, HBED-CC represents a highly attractive radiogallium chelator for high-stability labelling of radiopharmaceuticals. However, in contrast to other clinically well-established radiometal chelators, HBED-CC forms three NMR-distinguishable diastereomers (RR, RS and SS configurations at the amine nitrogens) during gallium complexation, whereas presumably the RR configuration is thermodynamically favoured [24]. Besides the influence of the temperature the formation of the diastereomers was reported to be pH- and concentration-dependent as well [23]. In a standard labelling protocol, [68Ga]Ga-PSMA-HBED-CC is incubated at a pH of ~4 and heated at 95 °C. The thermodynamically favoured diastereomer is formed; however, a small fraction of one of the other two diastereomers is still present in the labelling reaction and would be part of the final formulation prepared for the patient. Thus, it is of utmost importance to analyze the two major diastereomers according to their biological activity in cell-based assays. The aim of this study is to summarize hitherto existing radiochemical experiences with HBED-CC conjugated low-molecular weight compounds and to confirm that the configuration of Ga-HBED-CC does not influence the cell binding properties of the resulting PSMA-targeted radioligand [68Ga]Ga-PSMA-HBED-CC, especially since the chelator has high impact on the interaction with the aforementioned accessory hydrophobic pocket of PSMA. Owing to the high and growing clinical impact, this work aims to present novel important preclinical data of [68Ga]Ga-PSMA-HBED-CC and relevant aspects of its radiopharmaceutical production. The fully automated radiosynthesis as well as the essential quality control parameters according to current EU-GMP regulations for radiopharmaceuticals are given. 2. EXPERIMENTAL SECTION 2.1. Reagents and Chemical Syntheses The chemicals were of analytical grade and were used without further purification. Analysis of the synthesised molecules was performed using reversed-phase high performance liquid chromatography (RP-HPLC; Chromolith RP-18e, 100 mm × 4.6 mm; Merck, Darmstadt, Germany) with a linear A–B gradient (0% B to 100% B in 6 min) at a flow rate of 4 mL/min (analysis) or 6 mL/min (purification). Solvent A consisted of 0.1% aqueous trifluoroacetic acid (TFA) and solvent B was 0.1% TFA in acetonitrile. The HPLC system (L6200 A; Merck-Hitachi, Darmstadt, Germany) was equipped with a UV and a gamma detector (Bioscan, Washington, DC, USA). UV absorbance was measured at 214 nm and 254 nm. Mass spectrometry was performed with a MALDI-MS Daltonics Microflex system (Bruker Daltonics, Bremen, Germany). The natGa-labelled reference Glu-urea-Lys(Ahx)-[Ga(HBED-CC)] (DKFZ-GaPSMA-11) was purchased from ABX Advanced Biochemical Compounds (Radeberg, Germany) and dissolved in 40 μL CH3CN/H2O (1:1). 2.6 μg were characterised at RT by mass spectrometry using an Agilent 1200 HPLC-MS system connected to an Orbitrap Mass Spectrometer (Exactive, Thermo Fisher Scientific) on a Hypersil Gold C18 column (2.1 mm × 200 mm, 1.9 μm; Thermo Scientific, Bremen, Germany) eluted with a linear gradient (eluent A: 0.05% TFA in water; eluent B: 0.05% TFA in acetonitrile; 0%–30% B in 30 min at RT, flow rate: 0.2 mL/min, absorbance: λ = 214 nm). Full scan single mass spectra (positive mode) were obtained by scanning from m/z = 200–4000. The peptide c(RGDyK) was synthesised as described previously [26]. HBED-CC was conjugated by reacting with 1.2 equivalents of HBED-CC-TFP-ester which was synthesised as previously described [19]. The reaction mixture was supplemented with two equivalents of DIPEA in N,N-dimethylformamide (DMF). After HPLC purification (vide supra) the product was treated with TFA at room temperature for one hour resulting in the final compound. NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) conjugation was carried out by reacting the peptide with 3 equivalents of SCN-Bn-NOTA (purchased from Macrocyclics, Dallas, TX, USA) in 0.1 M sodium carbonate buffer (pH 9.5) for 20 h at room temperature. The reaction mixture was purified by semipreparative HPLC. Mass spectrometry was used to